Skip to content

Randomized,Controlled Clinical Trial of the external use of Ganyu Ointment for the treatment of Blood Heat Syndrome of Psoriasis Vulgaris

Randomized,Controlled Clinical Trial of the external use of Ganyu Ointment for the treatment of Blood Heat Syndrome of Psoriasis Vulgaris

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001280
Enrollment
Unknown
Registered
2026-05-26
Start date
2025-12-12
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Psoriasis

Interventions

Singular ordinal group:The left limb is treated with topical application of Gan Yu ointment
the right limb is treated with topical application of placebo
basic treatment involves oral administration of Chinese herbal decoction.
Even Number Group:External application of Ganyu ointment to the right limb, external application of placebo to the left limb, basic treatment: Oral administration of outpatient Chinese herbal decoctio

Sponsors

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1)Meets the diagnostic criteria for vulgaris psoriasis in Western medicine; 2) Meets the diagnostic criteria for the syndrome of blood heat in traditional Chinese medicine for psoriasis; 3) Aged between 18 and 65 years old (including 18 and 65 years old), with no restriction on gender; 4) Severity of condition: Mild to moderate skin lesion extent (BSA < 10%); 5) Patients are informed and agree to participate in the study, sign the relevant informed consent forms, voluntarily join the trial, and the informed consent process complies with GCP regulations.

Exclusion criteria

Exclusion criteria: 1)Within the past 12 weeks or 5 half-lives (whichever is longer), received treatment with biologics; within the past 2 weeks, received topical treatment with glucocorticoids, retinoids, or vitamin D3 derivatives; within the past 4 weeks, received phototherapy, bathing therapy, or other physical therapies. 2) History of severe primary diseases of the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems; history of mental illness; pregnancy, breastfeeding, or plans for conception within the next three months. 3) Allergy to the investigational drug. 4) Currently participating in other clinical trials of investigational drugs and receiving study medication. 5) Other situations deemed unsuitable for participation in the study by the investigator, such as the presence of other skin diseases that may interfere with assessment or treatment, potential compliance issues, inability to complete all required examinations and evaluations as per the protocol, or participation in the study involving uncontrollable risks.

Design outcomes

Primary

MeasureTime frame
Psoriasis Area and Severity Index;

Secondary

MeasureTime frame
Psoriasis Blood Heat Syndrome Main Clinical Symptom Scoring in Traditional Chinese Medicine;

Countries

China

Contacts

Public ContactZhou Dongmei

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

52176857@163.com13811201580

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026